Key factors
sym | ATNX |
exch | US |
MCap | 2333.68K |
Beta | 1.345 |
EPS | -10.4 |
Div date | 0000-00-00 |
Yesterday
sym | ATNX |
exch | US |
close | 0.006 |
50 Day MA | 0.946 |
200 Day MA | 3.354 |
52 Week High | 1.47 |
52 Week Low | 0.002 |
Target Price | 2.5 |
Market Cap Mln | 2.333 |
Share statistics
Shares Outstanding | 8703.1K |
Shares Float | 6501.48K |
Percent Institutions | 29.87 |
PercentInsiders | 9.733 |
SharesShort | 356.33K |
Short Ratio | 5.24 |
Shares Short Prior Month | 395.52K |
Short Percent | 5.180 |
Income
Revenue TTM | 102.82M |
Revenue Per Share TTM | 15.71 |
Quarterly Revenue Growth YOY | 110.89 |
Gross Profit TTM | 26.70M |
EBITDA | -71.8M |
Diluted Eps TTM | -10.4 |
earning
Operating Margin TTM | -0.72 |
EPS Estimate Current Quarter | -1.73 |
EPS Estimate Current Year | -4.5 |
EPS Estimate Next Quarter | -1.8 |
EPS Estimate Next Year | -1.52 |
Earnings Share | -10.4 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2023-02-15 |
Last Split Factor | 1:20 |
business
Enterprise Value Ebitda | -0.21 |
Enterprise Value Revenue | 0.269 |
Book Value /share | -0.75 |
Price Book MRQ | 1.077 |
Price Sales TTM | 0.200 |
ProfitMargin | -1.00 |
ReturnOnAssetsTTM | -0.19 |
ReturnOnEquityTTM | -19.2 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology & Medical Research |
Sector | Healthcare |
Codes
ISIN | US04685N1037 |
CIK | 1300699 |
Code | ATNX |
CUSIP | 04685N103 |
Employer Id Number | 43-1985966 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2023-09-24 |
is Delisted | 1 |
Delisted Date | 2023-07-26 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 269.0 |
IPODate | 2017-06-14 |
International Domestic | Domestic |
MostRecent Quarter | 2022-12-31 |
Contact
Name | Athenex Inc |
Address | Conventus Building, Buffalo, NY, United States, 14203 |
Country Name | USA |
Phone | 716 427 2950 |
Web URL | https://www.athenex.com |
Logo URL | /img/logos/US/ATNX.png |
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.